Concepedia

D.-W. Kim

DK

Statistics

Publications

7

Citations

654

H-Index

7

Active since

2010

Affiliations

Catholic University of Korea(Current)

The Catholic University of Korea Seoul St. Mary's Hospital

Chonnam National University Hwasun Hospital

Jena University Hospital

The University of Texas MD Anderson Cancer Center

D.-W. Kim is an author at Catholic University of Korea specializing in molecular oncology, medicine, and bcr-abl inhibitors.

Publications per year

2010–2019

7

Publications

7

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Neha Shah, D.-W. Kim, Hagop M. Kantarjian et al. · Haematologica · 2010 · 243 citations · Full text

, , +13

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

S.-E. Lee, Soo Young Choi, Ho Young Song et al. · Haematologica · 2016 · 165 citations · Full text

, , +14

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Franck E. Nicolini, A. R. Ibrahim, Simona Soverini et al. · Haematologica · 2013 · 80 citations · Full text

, , +13

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

S.-H. Kim, Hari Menon, Saengsuree Jootar et al. · Haematologica · 2014 · 70 citations · Full text

, , +13

Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia

J.-H. Yoon, Ho‐Young Yhim, Jae‐Yong Kwak et al. · Annals of Oncology · 2016 · 61 citations · Full text

, , +16

1–5 of 7